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The Role of the Thomsen-Friedenreich
Antigen As a Tumor-Associated Molecule
by Wolfgang Dippold,* Andrea Steinborn,* and
Karl-Hermann Meyer zum Buschenfelde*
The Thomsen-Friedenreich antigen (Gal-GalNAc) represents a tumor-associated molecule, which is
assumed to be one ofthe few chemically well-defined antigens with a proven association with malignancy.
In order to analyze the role of the carbohydrate structure Gal-GalNAc for gastrointestinal tumors, we
immunized Balb/c mice with MCF-7 breast tumor cells together with synthetic Gal-GalNAc linked to a
BSAcarrier. Onemonoclonalantibody(82-A6)wasestablishedwhichrecognizestheThomsen-Friedenreich
antigen according to the biochemical and serological analysis presented here. In contrast to the studies
performed in the past, immunohistochemical results using this antibody 82-A6 did not exhibit a reactivity
clearlyrestrictedtotumors. Preliminary biochemicalanalysisrevealedthattheT-determinantisdetectable
in the high-molecular weight range (about 1000 kD), suggesting that the Gal-GalNAc epitope is found on
mucinlike glycoproteins. Tumorrestriction ofThomsen-Friedenreich antigenmaythereforebedetermined
either by the protein backbone or by the 3-glycosidic linkage ofthe carbohydrate structure to the protein.
Introduction
During carcinogenesis, alterations occur in the bio-
synthesisofcarbohydrate structures onthe cell surface.
Therefore, carbohydrates linked either to proteins or
lipids are recognized as tumor-associated molecules
(1,2). An interesting novel approach to achieve tumor
immunity is to vaccinate patients with chemically syn-
thesized glycopeptides that are restricted to tumors.
Several investigators (3,4) have succeeded in generat-
ing glycopeptides with Gal-GalNAc residues coupled to
serine or threonine and bound to a carrier protein. This
structure has long been known as the Thomsen-Frie-
denreich antigen (T-antigen) (5). The T-antigen was ex-
tensively studied by Springer and his colleagues (6) and
believed to be tumor restricted. This antigen is the im-
mediate precursor of the human blood group MN an-
tigens, which are located in the NH2-terminal region of
the major sialoglycoprotein (glycophorin A) of human
erythrocytes. The immunodominant group ofthe T-an-
tigen [PGal (1-3) aGalNAc] is described as a cryptic
determinant on human erythrocytes, which is exposed
by neuraminidase treatment. This unmasked form has
beenreported to bepresent on mosthuman carcinomas.
Although it has been assumed that the tumor-asso-
ciated structure is immunologically similar to the T-
antigen expressed on desialylated red blood cells, no
*Department of Internal Medicine, Johannes Gutenberg Univer-
sity, D-6500 Mainz, Federal Republic ofGermany.
Address reprint requests to W. Dippold, Department of Internal
Medicine, Johannes GutenbergUniversity, Langenbeckstr. 1, D-6500
Mainz, Federal Republic of Germany.
one has yet defined the precise carbohydrate group or
characterized the molecule carrying the T-antigen de-
terminant on carcinomas. Therefore, we have tried to
establish a monoclonal antibody specific for T-antigen.
Results
An Antibody with Gal-GalNAc Specificity
By immunizing mice with the cultured tumor breast
cell line MCF-7 together with a synthetic, chemically
synthesized carbohydrate hapten [,PGal (1-3) aGalNAc-
serine + threonine] linked to a BSA carrier (bovine
serum albumin), we succeeded in generating a mono-
clonalantibody(82-A6, IgMsubclass)withT-specificity.
Fusion products of spleen cells and cells of the mouse
myeloma cell line P3-NS1/lAg 4-1 were grown in se-
lective media as previously described (7). The super-
natants were screened for antibody production, and
clones were selected on the basis of anti-T reactivity.
One clone (mAb 82-A6) was shown to bind to asialogly-
cophorin, but not to glycophorin, both of which were
obtained from Biocarb (Lund, Sweden). Moreover, the
antibody reacted with the purified asialoglycoproteins
ofboth the MM and NN blood groups. These asialogly-
coproteins differ in the polypeptide chain only.
To make sure that 82-A6bindingto asialoglycophorin
is dependent onthe carbohydrate residues ofthe eryth-
rocyte membrane protein, the purified protein was ex-
posed to NaBH4 in alkaline solution to separate the 0-
glycosidically linked Gal-GalNAc side chains from theDIPPOLD, STEINBORN, AND MEYER ZUM BUSCHENFELDE
Table 1. Specifity of the (Gal-GalNAc) mAb in comparison to peanut agglutinin.
Reactivity of
Antigen source Anti-T mAb Peanut agglutinin
Asialoglycophorina Positive Positive
Glycophorin (bloodgroup MM, NN) Negative Negative
Glycophorin, (bloodgroup MM, NN), Positive Positive
neuraminidase treated
Asialoglycophorin, NaBH4 Negative Negative
Red blood cells (A,B,O type)b Weakly positive Negative
Red blood cells (A,B,O type), neuraminidase Positive Positive
treated
aBinding of the mAb and peanut agglutinin to enzymatic and chemically treated glycophorin was tested by solid-phase immunosorbent
ELISA and by inhibition ELISA after preincubation of mAb with the antigen being tested. MAb- and biotin-conjugated peanut agglutinin
binding was visualized by using ,B-galactosidase-conjugated antimouse immunoglobulin or 13-galactosidase conjugated avidin.
bFor hemagglutination assays, red blood cells were incubated with mAb or peanut agglutinin for 30 min before and after neuraminidase
treatment. Agglutination results were scored by visual observation.
protein backbone. MAb binding to asialoglycophorin
was abolished after NaBH4 treatment.
Reactivity ofthe monoclonal antibody was studied by
ELISA assays of glycoproteins bound to polyvinyl mi-
crotiter plates (8). An additional inhibition assay using
asialoglycophorin as the target antigen was performed
to confirm the results obtained bythese direct tests and
yielded the same results.
Further analysis included reactivity of mAb 82-A6
with neuraminidase-treated red blood cells. Hemagglu-
tination was obtained with desialylated red blood cells
up to a titration end point of 200 ng/mL mAb 82-A6.
Agglutination ofuntreated red blood cells occurred only
at very high antibody concentrations and with an in-
cubation period of at least 5 min. Table 1 summarizes
theepitopeanalysisofamAb82-A6, demonstratingthat
the structure recognized represents the T-antigen.
Reactivity ofAnti-T mAb with Human
Tissues
To determine the tissue reactivity ofthe mAb 82-A6,
normal and malignant tissues were tested as summa-
Table 2. Reactivity of anti-T mAb with tumor cell lines and
tissues.a
Number of positive
Targets cell lines/tissues
Cell lines
Breast, MCF-7, CAMA, BT-20 3/3
Pancreas, Capan-1, -2, ASPC, QGP1 4/10
Stomach, Mz-Sto-1 1/2
Colon, HT-29 1/1
Liver, Mz-Hep-1 1/1
Kidney, SK-RC-6 1/1
Bladder, T-24 1/1
Melanoma, SK-Mel-19 1/3
Epithelial tumor tissues 35/52
Normal epithelial tissues 45/46
aTumor cell lines and cryostat sections obtained from fresh frozen
surgical specimen were immunostained with anti-T mAb 82-A6 ac-
cording to the indirect immunoperoxidase method. As negative con-
trol a monoclonal antibody to the mouse T-lymphocyte antigen Lyt
3.2 was used.
rized in Table 2. Cryostat sections offrozen specimens
were collected on glass slides, air dried, and stained by
the indirect immunoperoxidase method. MAb 82-A6 did
not show any tumor restriction and stained normal and
tumorous epithelial tissues equally well. The antibody
also reacted with the majority ofcultured human tumor
cell lines. In addition to well-known T-positive tumor
cell lines, binding sites for anti-T mAb were also found
on one of three melanomas. Nonnal peripheral blood
mononuclear cells (PBLs) did not express the T-antigen
using mAb 82-A6 by FACS analysis (fluorescent acti-
vating cell sorting). T-antigen was not revealed even
after treating PBLs with neuraminidase.
Molecular Weight of T-Antigen-Carrying
Proteins
Solubilized proteins of the human breast tumor cell
lineCAMAwereappliedtoamolecularweightexclusion
column (Superose 6, Pharmacia, Uppsala, Sweden).
Eluted proteins were tested for 82-A6 binding and de-
tected in the high molecular weight fractions of about
1000 kD size. These results suggest that the T-specific
carbohydrate epitope is expressed on mucinlike glyco-
proteins.
Conclusions
In this paper we describe a monoclonal antibody that
was generated following immunization of Balb/c mice
with a human tumor cell line known to express high
amounts of T-antigen together with a chemically syn-
thesized T-structure. The epitope recognized by mAb
82-A6 has been identified as T-antigen on the basis of
its reactivity with asialoglycophorin but not glyco-
phorin, its inability to bind deglycosylated asialogly-
cophorin, and theresults ofhemagglutination testswith
neuraminidase-treated red blood cells.
It appears noteworthy, however, that agglutination
of untreated red blood cells also occurred at very high
antibody concentrations and after longer incubation pe-
riods, which has neither been tested nor observed with
any other anti-T antibody. The antibody we describe
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here reacts with the Gal-GalNac structure, which is
linked by an a-glycosidic bond to serine and threonine.
Longenecker et al. have used a panel of a- and ,B-
glycosidically linked Gal-GalNAc structures bound to
carrier proteins for immunization (4). Their results in-
dicate that only by immunization with the 3-glycosidi-
cally linked disaccharide, and not with the a-glycosid-
ically linked one, was an mAb with some tumor re-
striction obtained. These findings are compatible with
our own results. Several other investigators have de-
scribed anti-T mAb (9-12). In no case, however, has
there been a detailed immunohistochemical analysis to
show that the antibodies are tumor restricted. Immu-
nohistochemical studies with mAb 82-A6 revealed that
T-antigen is not restricted to malignant tissues but is
also found in high amounts on normal tissues. These
results suggest that tumor restriction is either deter-
mined by the ,B-glycosidic linkage or depends on the
protein b.ackbone as indicated by studies ofSchlom and
his colleagues of the tumor antigen B72.3 (13).
The role of cx- or ,-glycosidic linkage in relation to
tumor association will only be clarified when synthetic
carbohydrate structures with definitively known ax- or
P-linkage to carrier proteins are available. Up to now
this has not been the case. Nevertheless, the antibody
and the test systems established so far may be useful
reagents to detect the real T-antigen, which has a ter-
minal Gal-GalNAc residue.
This work was supported by a Grant from the Deutsche For-
schungsgemeinschaft, SFB 302, project C-4.
REFERENCES
1. Hakomori, S. Aberrant glycosylation in cancer cell membranes
asfocused onglycolipids: overviewand perspectives. CancerRes.
45: 2405-2414 (1985).
2. Feizi, T. Demonstration by monoclonal antibodies that carbohy-
drate structures ofglycoproteins and glycolipids are onco-devel-
opmental antigens. Nature 314: 53-57 (1985).
3. Kunz, H., Birnbach, S. Synthese von O-Glycopeptiden des tu-
morassoziierten Tn- und T-Antigen-Typs und deren Anknupfung
anRinderserumalbumin. Angewandte Chemie98:354-355 (1986).
4. Longenecker, B. M., Willans, D. J., Mac Lean, G. D., Selvaraj,
S., Suresh, M. R., and Joujaim, A. Monoclonal antibodies and
synthetic tumor-associated glycoconjugates in the study of the
expression ofThomsen-Friedenreich-like and Tn-like antigens on
human cancers. JNCI 78: 489-496 (1987).
5. Uhlenbruck, G. The Thomsen-Friedenreich (TF) receptor: an old
history with new mystery. Immunol. Commun. 10: 251-264
(1981).
6. Springer, G. F. T and Tn, general carcinoma autoantigens. Sci-
ence 224: 1198-1205 (1984).
7. Dippold, W., Lloyd, K. O., Li L. T. C. Ikeda, H., Oettgen, H.
F., Old, L.J. Cellsurfaceantigens ofhumanmalignantmelanoma:
definition of six antigenic systems with monoclonal antibodies.
Proc. Natl. Acad. Sci. USA 77: 6114-6118 (1980).
8. Dippold, W., Bernhard, H., Klingel, R., Dienes, H. P., Kron,
G., Schneider, B., Knuth, A., Meyer zum Buschenfelde, K.-H.
A common epithelial cell surface antigen EPM-1 on gastrointes-
tinaltumorsandinhumansera. CancerRes. 47: 3873-3879(1987).
9. Clausen, H., Stroud, M., Parker, J., Springer, G., Hakomori, S.
Monoclonal antibodies to the blood group A associated structure
galactosyl-A: specificity and relation to the Thomsen-Frieden-
reich antigen. Mol. Immunol. 24: 199-204 (1988).
10. Metcalfe, S., Springer, G. F., Svvennsen, R. J., Tegtmeyer, H.
Monoclonal antibodies specific for human Thomsen-Friedenreich
T and Tn blood group precursor antigens. In: Protides of the
Biological Fluids, Vol. 32 (H. Peeters, Ed.); Pergamon Press,
Oxford, 1985, pp. 759-763.
11. Rahman, A. F. R., Longenecker, B. M. A monoclonal antibody
specific for the Thomsen-Friedenreich cryptic T-antigen. J. Im-
munol. 129: 2021-2024 (1982).
12. Stein, R., Chen, S., Grossman, W., Goldberg, D. M. Human lung
carcinoma monoclonal antibody specific for the Thomsen-Frie-
denreich antigen. Cancer Res. 49: 32-37 (1989).
13. Johnson, V. G., Schlom, J., Paterson, A. J., Bennett, Jr., Mag-
nani, J. L., Colcher, D. Analysis of a human tumor-associated
glycoprotein (TAG-72) identified by monoclonal antibody B72.3.
Cancer Res. 46: 850-857 (1986).